Clinical Data Survodutide delivers 16.6% weight loss in major phase 3 obesity trial PharmaTimesBoehringer Ingelheim reports significant reductions in weightMetabolic & GLP-1Read full story pharminent April 30, 2026 (Last updated: April 30, 2026) PharmaTimes Boehringer Ingelheim reports significant reductions in weight Metabolic & GLP-1 Read full story Post navigation Previous: Avalyn, in pursuit of better lung drugs, banks $300M in an IPONext: Ray Therapeutics receives EMA PRIME status for gene therapy Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026